Latest News

(UroToday.com) The TITAN randomized phase 3 study compared apalutamide to placebo in combination with androgen deprivation therapy for treatment of men with metastatic castration sensitive prostate cancer (mCSPC).1 The co-primary endpoints of the study were overall survival and radiographic progression free survival. The study schema is shown below. 

(UroToday.com) In this discussion, Dr. Alumkal discussed two presentations looking at molecular correlates of response to apalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) and data from the ACIS trial of androgen annihilation with abiraterone and apalutamide in chemotherapy naïve mCRPC. 

(UroToday.com) Pembrolizumab, an anti-PD-1 antibody, has antitumor activity as monotherapy in patients with heavily pre-treated, PD-L1 positive advanced prostate cancer as well as mCRPC patients regardless of PD-L1 expression status. KEYNOTE-365 is a 4-cohort study evaluating the combination of pembrolizumab in combination with multiple agents, as shown below. Results from Cohort B, the combination of […]

(UroToday.com) In this presentation, Dr. de Bono summarized results of the IPATential150 trial, previously presented at ESMO 2020, which demonstrated an rPFS benefit for the combination of the AKT-inhibitor ipatasertib with abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC). This benefit was seen in the intention to treat population as well as when patients were […]

(UroToday.com) The CheckMate 9KD trial is a multi-arm open label phase 2 study evaluating the efficacy of the anti-PD-1 antibody nivolumab in combination with other therapies such as docetaxel, rucaparib or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). The rationale for the combination of nivolumab with docetaxel is that docetaxel is a standard of care therapy […]

(UroToday.com) While advanced bladder cancer has a generally poor prognosis, there are notable gender-based differences. While women have a lower incidence of bladder cancer, they are, in general, diagnosed with more advanced disease at presentation. Further, even when tumor stage and treatment approach are accounted for, women have worse outcomes. However, the basis of these discrepancies […]

(UroToday.com) Platinum-based cytotoxic chemotherapy has been the standard of care for patients with advanced urothelial carcinoma (UC) based on improved survival compared to placebo. However, objective response rates are at best 50% and median overall survival is relatively poor at less than 18 months. As a result, there have been numerous efforts to improve these outcomes. […]

(UroToday.com) Advanced urothelial carcinoma has among the worst prognosis for tumors treated by genitourinary oncologists. Standard of care dictates that patients receive platinum-based induction chemotherapy. However, even with this treatment, rates of recurrence and disease progression are high and overall survival is quite short due to the development of chemotherapy resistance.

(UroToday.com) Platinum-based cytotoxic chemotherapy has been the standard of care for patients with advanced urothelial carcinoma (UC) based on improved survival compared to placebo. However, objective response rates are at best 50% and median overall survival is relatively poor at less than 18 months. As a result, there have been numerous efforts to improve these outcomes. […]

(UroToday.com) Advanced urothelial carcinoma has among the worst prognosis for tumors treated by genitourinary oncologists. Standard of care dictates that patients receive platinum-based induction chemotherapy. However, even with this treatment, rates of recurrence and disease progression are high and overall survival is quite short due to the development of chemotherapy resistance. Subsequent treatments may include […]